Claims for Patent: 9,060,976

Summary for Patent: 9,060,976

Title:	Pharmaceutical formulation containing gelling agent
Abstract:	Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
Inventor(s):	Wright; Curtis (Rockport, MA), Oshlack; Benjamin (Boca Raton, FL), Breder; Christopher (Greenwich, CT)
Assignee:	Purdue Pharma L.P. (Stamford, CT) The P.F. Laboratories, Inc. (Totowa, NJ) Purdue Pharmaceuticals L.P. (Wilson, NC)
Application Number:	13/726,324
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,060,976
Patent Claims:	1. An extended release abuse deterrent dosage form comprising: a. a core matrix comprising a blended mixture of: (a) PEO having a molecular weight of from about 300,000 daltons to about 5,000,000 daltons; (b) magnesium stearate; and (c) oxycodone or a pharmaceutically acceptable salt thereof; wherein the core matrix is heated to melt at least a portion of the PEO included in the core matrix during preparation of the dosage form; and b. PEG applied onto the core matrix; wherein the dosage form provides extended release of the drug.